ICON Public (NASDAQ:ICLR) Receives Outperform Rating from William Blair

William Blair reissued their outperform rating on shares of ICON Public (NASDAQ:ICLR) in a report published on Tuesday,Benzinga reports.

Several other research firms also recently issued reports on ICLR. Truist Financial reiterated a “buy” rating and set a $284.00 price target (down previously from $295.00) on shares of ICON Public in a research note on Wednesday, December 18th. Evercore ISI lowered their price target on ICON Public from $360.00 to $350.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. StockNews.com lowered shares of ICON Public from a “buy” rating to a “hold” rating in a research report on Thursday, September 19th. JPMorgan Chase & Co. decreased their price objective on shares of ICON Public from $375.00 to $280.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Finally, Barclays dropped their target price on shares of ICON Public from $330.00 to $275.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. Four equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $287.00.

ICON Public Trading Up 1.5 %

NASDAQ:ICLR opened at $202.47 on Tuesday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34. The company has a market capitalization of $16.70 billion, a P/E ratio of 22.57, a P/E/G ratio of 1.59 and a beta of 1.20. The stock’s 50 day moving average price is $210.30 and its 200 day moving average price is $269.51. ICON Public has a 52 week low of $183.38 and a 52 week high of $347.72.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The business had revenue of $2.03 billion for the quarter, compared to the consensus estimate of $2.13 billion. ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The firm’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.10 EPS. On average, research analysts forecast that ICON Public will post 13.41 EPS for the current fiscal year.

Institutional Trading of ICON Public

Several institutional investors have recently modified their holdings of ICLR. Steph & Co. raised its stake in shares of ICON Public by 3.7% in the fourth quarter. Steph & Co. now owns 1,560 shares of the medical research company’s stock valued at $327,000 after purchasing an additional 55 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of ICON Public by 64.0% during the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after acquiring an additional 169 shares in the last quarter. Foyston Gordon & Payne Inc bought a new stake in ICON Public in the third quarter valued at about $11,672,000. Icon Wealth Advisors LLC raised its position in ICON Public by 861.1% in the third quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock worth $3,797,000 after purchasing an additional 11,840 shares in the last quarter. Finally, First Horizon Advisors Inc. lifted its stake in ICON Public by 33.9% during the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock worth $172,000 after purchasing an additional 151 shares during the period. Institutional investors and hedge funds own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.